Abatacept, adalimumab equivalent for RA in 2-year head-to-head trial

Описание к видео Abatacept, adalimumab equivalent for RA in 2-year head-to-head trial

A 2-year head-to-head comparison of abatacept and adalimumab in rheumatoid arthritis patients who were on background methotrexate has found equal improvement with both biologics, according to results from a study presented at the annual European Congress of Rheumatology. Dr. Michael Schiff discusses the results. See the related story at http://www.rheumatologynews.com

Комментарии

Информация по комментариям в разработке